POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions for cellular electrochemical activity; dextrose is a caloric agent that increases blood glucose levels; sodium chloride is an electrolyte replenisher that maintains osmotic balance and fluid distribution.
| Metabolism | Potassium: primarily excreted unchanged by kidneys; Dextrose: metabolized via glycolysis and tricarboxylic acid cycle to carbon dioxide and water; Sodium chloride: not metabolized, excreted primarily by kidneys. |
| Excretion | Potassium is primarily excreted renally (>90%) via glomerular filtration and distal tubular secretion; a small fraction (approximately 10%) is lost via feces, with minimal biliary excretion. Sodium and chloride are likewise predominantly eliminated in urine (>95%). Dextrose is metabolized to CO2 and water. |
| Half-life | No defined half-life for the combined product; potassium has an elimination half-life of approximately 2–3 hours in healthy individuals, though it is highly dependent on renal function and body stores. Dextrose and sodium chloride are rapidly distributed and eliminated with half-lives of 15–30 minutes and 2–4 hours, respectively. |
| Protein binding | Potassium: negligible protein binding (<1%); dextrose: not bound; sodium and chloride: not bound. |
| Volume of Distribution | Potassium: 0.4–0.7 L/kg (total body water); dextrose: 0.2 L/kg (extracellular fluid); sodium and chloride: 0.2–0.3 L/kg (extracellular fluid). |
| Bioavailability | Intravenous: 100% bioavailable. Not administered via other routes. |
| Onset of Action | Intravenous (IV) infusion: Potassium begins to correct hypokalemia within minutes; dextrose and sodium chloride exert osmotic and volume effects immediately upon infusion. |
| Duration of Action | IV infusion: Potassium effects last hours after infusion ceases, depending on redistribution and renal excretion; dextrose effect is short (30–60 minutes post-infusion); sodium chloride volume effect lasts 1–2 hours after infusion. |
Continuous IV infusion at a rate of 0.5-1 L/hr, providing potassium 10-20 mEq/hr, dextrose 10 g/hr, and sodium chloride 154 mEq/L; administer via central or peripheral line as a maintenance or replacement solution. Adjust rate based on serum potassium, glucose, and sodium levels and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of hyperkalemia; for GFR 30-60 mL/min, use with caution, monitor serum potassium closely, and reduce infusion rate by 50% or use lower potassium concentration; not recommended when GFR <30 mL/min. |
| Liver impairment | No dose adjustment required for Child-Pugh class A or B; for Child-Pugh class C (severe hepatic impairment), use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor serum potassium and glucose levels frequently. |
| Pediatric use | IV infusion based on weight: potassium 0.5-1 mEq/kg/day, dextrose 10-15 g/kg/day, sodium chloride 2-4 mEq/kg/day; typical rate 100-150 mL/kg/day for maintenance; adjust based on serum electrolytes and glucose; contraindicated in neonates with hyperkalemia and in patients with renal impairment. |
| Geriatric use | Initiate at lower infusion rates (0.3-0.5 L/hr) and monitor serum potassium, glucose, and renal function closely due to age-related decline in GFR and altered glucose tolerance; consider reduced dextrose content if hyperglycemia occurs; avoid in patients with significant fluid overload or heart failure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium chloride, dextrose, and sodium chloride are considered compatible with breastfeeding. M/P ratio not determined. Potassium and sodium are normal milk constituents; intravenous administration minimally affects milk composition. Monitor infant for electrolyte imbalances if mother receives high doses. |
| Teratogenic Risk | Pregnancy category C. First trimester: No evidence of major malformations from potassium or dextrose; sodium component may cause fluid shifts. Second and third trimesters: High doses may cause fetal hyperkalemia or acid-base disturbances. No human studies adequately assess risk. |
■ FDA Black Box Warning
Potassium chloride concentrate must be diluted before use; injection of undiluted potassium chloride can cause cardiac arrest or fatal hyperkalemia. Not for direct intravenous injection.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Hypernatremia","Hyperglycemia","Patients with anuria or severe renal impairment","Patients with elevated blood glucose levels (e.g., diabetic coma)","Concurrent use of potassium-sparing diuretics or ACE inhibitors without careful monitoring"]
| Precautions | ["Use with caution in patients with severe renal impairment, heart failure, or conditions predisposing to hyperkalemia","Monitor serum potassium, sodium, glucose, and fluid balance","Risk of hyperglycemia in patients with diabetes mellitus or impaired glucose tolerance","Risk of fluid overload in patients with cardiac or renal disease"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum potassium, sodium, glucose, and acid-base status. Assess fetal heart rate during infusion for signs of maternal electrolyte imbalance. Avoid rapid infusion to prevent fetal distress from osmotic shifts. |
| Fertility Effects | No known adverse effects on fertility. Potassium chloride and dextrose do not impair reproductive function. Sodium chloride at standard doses does not affect fertility. |